184.89 0.00 (0.00%)
After hours: 4:24PM EDT
|Bid||182.00 x 900|
|Ask||199.10 x 800|
|Day's Range||181.60 - 188.89|
|52 Week Range||126.50 - 278.62|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||37.41|
|Earnings Date||Nov 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||257.33|
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
For whatever the reason — the trade war, Federal Reserve or general market malaise — investors have turned on a variety high-momentum shares. The rout in biotech stocks has been pretty severe. The iShares NASDAQ Biotechnology Index (NYSEARCA:IBB) — the broad sector benchmark — is down roughly 5% in October.
Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2018 financial results on November 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Ligand Pharmaceuticals (LGND) closed at $202.59 in the latest trading session, marking a -1.5% move from the prior day.
Top market leaders continued to show bearish selling, with many taking out their 50-day moving averages. Microsoft also undercut its 50-day line.
Ligand Pharmaceuticals Incorporated (LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of Ligand. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing collaborations. In conjunction with this event, Ligand announced that its portfolio now contains more than 178 shots on goal.
Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first.
COLUMBUS, Ohio, Oct. 09, 2018 -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific.
bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
This trio is not big or small, but each offers investors a potentially huge long-term investment opportunity... if you take action right now
Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
U.S. stock indexes advanced late Wednesday morning as the Nasdaq headed toward its best price and volume action in nine sessions. Three financial reports pointed to a strengthening economy. [ibd-display-video id=3774806 width=50 float=left autostart=true] The Nasdaq popped 0.
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Ligand Pharmaceuticals Inc (NASDAQ: LGND) is a unique type of biotech company. This is the new age of biotech companies and LGND is a prime example of how it should be done. CyberArk Software Inc (NASDAQ: CYBR) is in one of the hottest and most important tech sectors for the next decade or more – cybersecurity.
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO), my choice for the InvestorPlace Best ETFs for 2018 competition, is enduring its worst quarter of 2018. With just a few trading days left in the third quarter, SBIO is sporting a quarter-to-date loss of 0.2%.
The technology sector climbed Thursday, helping the Nasdaq composite lead. But the health care sector was even stronger.
Ligand Pharmaceuticals (LGND) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
True market leader Netflix, producer of award-winning shows such as "The Crown," is showing bullish action in recent weeks.